Company profile
UK company 06926173, incorporated on 6 June 2009.
Biomoti Limited is a UK company with status active founded in 2009 based in West Midlands.
Company number 06926173
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
Biomoti was created to develop our drug delivery platform, initially building a lead candidate for the treatment of ovarian cancer, Oncojan.
BioMoti develops immunotherapeutic microparticles whose role is to enter cancer cells and release drugs within it.
BioMoti had a succesful first seed funding round, was shortlisted in the Best Emerging Biotech category (Sponsored by James Cowper) alongside Atopix Therapeutics and Autifony Therapeutics for the OBN Awards 2013, and has won an MRC studentship award with QMUL.
1 Mar 2018 to 28 Feb 2019
"Cancer is the second leading cause of global mortality with over 8,000,000 deaths worldwide (WHO, 2015) and 163,444 in the UK (CRUK, 2014). There continues to be large unmet clinical need for patients with certain cancers such as ovarian where median survival is only 3 years. These survival rates have not changed for the past 3 decades. BioMoti, in a new...
1 Aug 2017 to 31 Oct 2019
Cancer is the second leading cause of global mortality with over 8,000,000 deaths worldwide (WHO, 2015) and 163,444 in the UK (CRUK, 2014). Interventions that leverage the immune system, including antibodies and cell-based therapies, promise to revolutionise cancer treatment with cures seen in previously untreatable patients. However, many obstacles remai...
1 Apr 2013 to 31 Mar 2014
One in three of us will get cancer and increases in life expectancy indices will only exacerbate this statistic. Unfortunately, many cancer subtypes have very poor survival rates. Most chemotherapeutics have devastating side effects such as hair loss, nausea, weakened immunity and fatigue. BioMoti is developing an exciting technology platform based on Que...
